Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid Tumors

Video

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

“The worry when we started was that we wouldn't see benefit, but we've seen it. So this really does 2 things. Number 1, it's an avenue for treatment for a significant subset of patients with advanced malignancy... But significantly, if this strategy is successful, this may open the world of T-cell therapies to the solid tumor world, in a way that we really have not had access to [in a large scale with] CAR-T or tumor-infiltrating lymphocyte therapies, due to the limitations of those modalities.”

Triumvira Immunologics’ TAC01-HER2, an investigational HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, is currently being evaluated in the phase 1/2 TACTIC-2 clinical trial(NCT04727151) for the treatment of patients with HER-2 positive solid tumors.

Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute, an investigator for the trial, recently presented data from TACTIC-2 at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, in Paris, France, and virtually.

In an interview with CGTLive, Schlechter discussed the key findings that have come out of the clinical trial so far, highlighting a patient’s objective response at 29 days as particularly impressive. He also went over what he sees as the potential advantages of TAC01-HER2 compared to the current standard of care for patients with HER2-positive solid tumors. Schlechter additionally discussed some challenges of the current trial and potential areas for further study. He concluded by recommending a re-examination of immunotherapy naming conventions in order to make the terminology more descriptive and educational for both the broader clinical community and patients.

Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.